Skip to content

A Study to Compare Two Treatments for Parkinson s Disease: Habb-e-Ishrat and Levodopa-Carbidopa.

AN OPEN-LABEL, PARALLEL-ARM, RANDOMIZED COMPARATIVE STUDY ASSESSING THE SAFETY OF HABB-E-ISHRAT AND LEVODOPA-CARBIDOPA TO DOWNSIZE THE CLINICAL SCENARIO OF MARZ-E-PARKINSON (PARKINSON s DISEASE) - Nil

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/02/102865
Enrollment
30
Registered
2026-02-03
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G20- Parkinsons disease

Interventions

Intervention1: HABB-E-ISHRAT: 1.Filfil siyah (Piper nigrum Linn) 10 grams 2.Zanjabeel (Zingiber officinale Roscoe) 10 grams 3.Aamla (Emblica officianalis Gaertn) 10 grams 4.Saad Kufi (Cyperus rotundus

Sponsors

Government Nizamia Tibbi college and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Hoehn and Yahr stage 1 to 3 (corresponding to mild to moderate disease). 2. MDS-UPDRS Part III (Motor Examination) score between 10 and 45, indicating mild to moderate motor impairment. 3. Able to give informed consent and comply with study procedures. 4. Presence of tremor or rigidity as a chief complaint.

Exclusion criteria

Exclusion criteria: 1. Secondary Parkinsonism (e.g. drug induced or post encephalitic) 2. Sever cognitive impairment or psychiatric illness 3. Patient with co-morbidities like uncontrolled DM (FBS:greater than 150mg/dl, PLBS:greater than 250mg/dl, HBA1C: greater than 8gm%), Uncontrolled HTN (systolic: greater than 160-179mm of Hg, diastolic: greater than 100-109mm of Hg Acc to AHA/ACC) cardiac disorders, renal failures. 4. Known hypersensitivity to trial drugs. 5. Pregnant or lactating women. 6. Chronic alcoholics. 7. Immuno-compromised patients.

Design outcomes

Primary

MeasureTime frame
Change in PDQ 39 from baseline to Week 12. Timepoint: 3 Months, with 6 follow ups at an interval of 15 days.

Secondary

MeasureTime frame
Change in UPDRS - III (Motor from Baseline to Week 12 (Baseline Inclusion UPDRS III 10-45).Timepoint: 3 Months, with 6 follow ups at an interval of 15 days.

Countries

India

Contacts

Public ContactDr ASMA SULTANA

Government Nizamia Tibbi college and Hospital

drsakhussaini@gmail.com9704888561

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026